DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, BELARUS, HONGKONG, JAPAN...
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...
Vid extra bolagsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 14 december 2023 fattades följande beslut. ...
Vid årsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 14 december 2023 fattades de beslut som beskrivs ned...
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along wi...
Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, shares an updat...
Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cance...
